Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients.

@article{Bourgeois2006PhaseIS,
  title={Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients.},
  author={Hugues Bourgeois and Florence Joly and {\'E}ric Pujade-Lauraine and Herv{\'e} D Cur{\'e} and Jean Paul Guastalla and Aur{\'e}lie Ferru and Virginie Chabrun and St{\'e}phanie Chi{\`e}ze and J. M. Tourani},
  journal={American journal of clinical oncology},
  year={2006},
  volume={29 4},
  pages={399-404}
}
OBJECTIVES To determine the dose limiting toxicity, the maximum tolerated dose and the recommended dose of pegylated liposomal doxorubicin (PLD) in association with a fixed dose of ifosfamide (IFO) to patients with recurrent, advanced ovarian cancer (AOC). METHODS Patients with progressing platinum-sensitive or resistant disease were included in 5 dose levels consisting of PLD (25 mg/m2 to 45 mg/m2, day 1) combined with a fixed IFO dose administered as a continuous infusion (1700 mg/m2/d, day… CONTINUE READING

Similar Papers

Loading similar papers…